The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia

Journal of Controlled Release

Volumn 223, Issue , 2016, Pages 1-10

  Tomalova, Barbora ^a   Sirova, Milada ^a   Rossmann, Pavel ^a   Pola, Robert ^b   Strohalm, Jiri ^b   Chytil, Petr ^b   Cerny, Viktor ^a   Tomala, Jakub ^a   Kabesova, Martina ^a   Rihova, Blanka ^a   Ulbrich, Karel ^b   Etrych, Tomas ^b   Kovar, Marek ^a  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^b INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

Author keywords

Anti tumour activity; Doxorubicin; HPMA; Structure; Toxicity

Indexed keywords

DISEASES; DRUG DELIVERY; FILTRATION; MAMMALS; ONCOLOGY; POLYMERS; STARS; STRUCTURE (COMPOSITION); T-CELLS; TOXICITY;

DOXORUBICIN; DRUG DELIVERY SYSTEM; GLOMERULAR FILTRATION; HIGH MOLECULAR WEIGHT; HPMA; HPMA COPOLYMER CONJUGATES; MAXIMUM TOLERATED DOSE; POLYMERIC CONJUGATES;

TUMORS;

DOXORUBICIN; N (2 HYDROXYPROPYL)METHACRYLAMIDE; ACRYLAMIDE DERIVATIVE; ANTINEOPLASTIC ANTIBIOTIC; DENDRIMER; DRUG CARRIER; N-(2-HYDROXYPROPYL)METHACRYLAMIDE CO-POLYMER-DOXORUBICIN CONJUGATE; PAMAM STARBURST;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; THERAPEUTIC INDEX; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; BONE MARROW; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; FEMALE; INTESTINE; LIVER; METABOLISM; MOLECULAR WEIGHT; NEOPLASMS; PATHOLOGY; SPLEEN; TUMOR CELL LINE;

ACRYLAMIDES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BONE MARROW; CELL LINE, TUMOR; DENDRIMERS; DOXORUBICIN; DRUG CARRIERS; FEMALE; INTESTINES; LIVER; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOLECULAR WEIGHT; NEOPLASMS; SPLEEN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84961346074     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.12.023     Document Type: Article

References (31)

1. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer-chemotherapy - mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392
2. H. Hashizume, P. Baluk, S. Morikawa, J.W. McLean, G. Thurston, S. Roberge, R.K. Jain, and D.M. McDonald Openings between defective endothelial cells explain tumor vessel leakiness Am. J. Pathol. 156 2000 1363 1380
3. S. Taurin, H. Nehoff, and K. Greish Anticancer nanomedicine and tumor vascular permeability; where is the missing link? J. Control. Release 164 2012 265 275
4. H. Kobayashi, R. Watanabe, and P.L. Choyke Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics 4 2014 81 89
5. B. Theek, F. Gremse, S. Kunjachan, S. Fokong, R. Pola, M. Pechar, R. Deckers, G. Storm, J. Ehling, F. Kiessling, and T. Lammers Characterizing EPR-mediated passive drug targeting using contrast-enhanced functional ultrasound imaging J. Control. Release 182 2014 83 89
6. U. Prabhakar, H. Maeda, R.K. Jain, E.M. Sevick-Muraca, W. Zamboni, O.C. Farokhzad, S.T. Barry, A. Gabizon, P. Grodzinski, and D.C. Blakey Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology Cancer Res. 73 2013 2412 2417
7. H. Maeda Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity Adv. Drug Deliv. Rev. 2015
8. J. Kopecek, and P. Kopeckova HPMA copolymers: origins, early developments, present, and future Adv. Drug Deliv. Rev. 62 2010 122 149
9. S. Kunjachan, R. Pola, F. Gremse, B. Theek, J. Ehling, D. Moeckel, B. Hermanns-Sachweh, M. Pechar, K. Ulbrich, W.E. Hennink, G. Storm, W. Lederle, F. Kiessling, and T. Lammers Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines Nano Lett. 14 2014 972 981
10. J. Kopecek, I. Cifkova, P. Rejmanova, J. Strohalm, B. Obereigner, and K. Ulbrich Polymers containing enzymatically degradable bonds.4. Preliminary experiments in vivo Makromol. Chem. 182 1981 2941 2949
11. P. Rejmanova, J. Kopecek, R. Duncan, and J.B. Lloyd Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl) methacrylamide copolymers Biomaterials 6 1985 45 48
12. T. Etrych, M. Jelinkova, B. Rihova, and K. Ulbrich New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties J. Control. Release 73 2001 89 102
13. K. Ulbrich, T. Etrych, P. Chytil, M. Jelinkova, and B. Rihova HPMA copolymers with pH-controlled release of doxorubicin - in vitro cytotoxicity and in vivo antitumor activity J. Control. Release 87 2003 33 47
14. B. Rihova, T. Etrych, M. Pechar, M. Jelinkova, M. Stastny, O. Hovorka, M. Kovar, and K. Ulbrich Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes J. Control. Release 74 2001 225 232
15. T. Etrych, V. Subr, J. Strohalm, M. Sirova, B. Rihova, and K. Ulbrich HPMA copolymer-doxorubicin conjugates: the effects of molecular weight and architecture on biodistribution and in vivo activity J. Control. Release 164 2012 346 354
16. T. Etrych, J. Strohalm, P. Chytil, P. Cernoch, L. Starovoytova, M. Pechar, and K. Ulbrich Biodegradable star HPMA polymer conjugates of doxorubicin for passive tumor targeting Eur. J. Pharm. Sci. 42 2011 527 539
17. J.Q. Lu, W.C. Zhao, H. Liu, R. Marquez, Y.X. Huang, Y.F. Zhang, J. Li, W. Xie, R. Venkataramanan, L. Xu, and S. Li An improved D-alpha-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance J. Control. Release 196 2014 272 286
18. U. Vanhoefer, S. Cao, A. Harstrick, S. Seeber, and Y.M. Rustum Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP) Ann. Oncol. 8 1997 1221 1228
19. S. Van, S.K. Das, X.H. Wang, Z.L. Feng, Y. Jin, Z. Hou, F. Chen, A. Pham, N. Jiang, S.B. Howell, and L. Yu Synthesis, characterization, and biological evaluation of poly(l-gamma-glutamyl-glutamine)-paclitaxel nanoconjugate Int. J. Nanomedicine 5 2010 825 837
20. T.K. Stutchbury, F. Al-Ejeh, G.E. Stillfried, D.R. Croucher, J. Andrews, D. Irving, M. Links, and M. Ranson Preclinical evaluation of Bi-213-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma Mol. Cancer Ther. 6 2007 203 212
21. R.W.H.M. Staffhorst, K. van der Born, C.A.M. Erkelens, I.H.L. Hamelers, G.J. Peters, E. Boven, and A.I.P.M. de Kroon Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts Anti-Cancer Drugs 19 2008 721 727
22. S. Viaud, F. Saccheri, G. Mignot, T. Yamazaki, R. Daillere, D. Hannani, D.P. Enot, C. Pfirschke, C. Engblom, M.J. Pittet, A. Schlitzer, F. Ginhoux, L. Apetoh, E. Chachaty, P.L. Woerther, G. Eberl, M. Berard, C. Ecobichon, D. Clermont, C. Bizet, V. Gaboriau-Routhiau, N. Cerf-Bensussan, P. Opolon, N. Yessaad, E. Vivier, B. Ryffel, C.O. Elson, J. Dore, G. Kroemer, P. Lepage, I.G. Boneca, F. Ghiringhelli, and L. Zitvogel The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide Science 342 2013 971 976
23. B. Rihova, and M. Kovar Immunogenicity and immunomodulatory properties of HPMA-based polymers Adv. Drug Deliv. Rev. 62 2010 184 191
24. T. Etrych, V. Subr, R. Laga, B. Rihova, and K. Ulbrich Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: impact of the carrier structure onto synergistic action in the treatment of solid tumours Eur. J. Pharm. Sci. 58 2014 1 12
25. B. Rihova, M. Bilej, V. Vetvicka, K. Ulbrich, J. Strohalm, J. Kopecek, and R. Duncan Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin - immunogenicity, and effect on hematopoietic stem-cells in bone-marrow invivo and mouse splenocytes and human peripheral-blood lymphocytes in vitro Biomaterials 10 1989 335 342
26. B. Rihova, J. Kopecek, K. Ulbrich, M. Pospisil, and P. Mancal Effect of the chemical-structure of N-(2-hydroxypropyl)methacrylamide copolymers on their ability to induce antibody-formation in inbred strains of mice Biomaterials 5 1984 143 148
27. O. Tacar, P. Sriamornsak, and C.R. Dass Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems J. Pharm. Pharmacol. 65 2013 157 170
28. T. Lammers, F. Kiessling, W.E. Hennink, and G. Storm Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress J. Control. Release 161 2012 175 187
29. C. Wong, T. Stylianopoulos, J.A. Cui, J. Martin, V.P. Chauhan, W. Jiang, Z. Popovic, R.K. Jain, M.G. Bawendi, and D. Fukumura Multistage nanoparticle delivery system for deep penetration into tumor tissue Proc. Natl. Acad. Sci. U. S. A. 108 2011 2426 2431
30. M.R. Dreher, W.G. Liu, C.R. Michelich, M.W. Dewhirst, F. Yuan, and A. Chilkoti Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers J. Natl. Cancer Inst. 98 2006 335 344
31. Z. Popovic, W.H. Liu, V.P. Chauhan, J. Lee, C. Wong, A.B. Greytak, N. Insin, D.G. Nocera, D. Fukumura, R.K. Jain, and M.G. Bawendi A nanoparticle size series for in vivo fluorescence imaging Angew. Chem. Int. Ed. 49 2010 8649 8652